| NCT ID | NCT05187312 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Stockholm |
| Condition | Cholangiocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2022-01-14 |
| Primary Completion | 2032-01-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2022-01-14 with a primary completion date of 2032-01-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Observational registry including endoscopic diagnostic and therapeutic interventions in the gastrointestinal tract
Eligibility Criteria
Inclusion Criteria: * Clinical indication for endoscopic intervention/procedure Exclusion Criteria: * No informed consent * Age \<18 years
Contact & Investigator
Erik von Seth, MD, PhD
PRINCIPAL INVESTIGATOR
Region Stockholm
Frequently Asked Questions
Who can join the NCT05187312 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cholangiocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05187312 currently recruiting?
Yes, NCT05187312 is actively recruiting participants. Contact the research team at erik.von.seth@ki.se for enrollment information.
Where is the NCT05187312 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT05187312 clinical trial?
NCT05187312 is sponsored by Region Stockholm. The principal investigator is Erik von Seth, MD, PhD at Region Stockholm. The trial plans to enroll 1,000 participants.